1-15 of 181
Finerenone in IgAN: A Proteinuria Signal Worth Following
Clinician's RoundtableFinerenone in IgAN: A Proteinuria Signal Worth Following
Green Tea Compound Shows Potential to Protect Podocytes in FSGS
Clinician's RoundtableGreen Tea Compound Shows Potential to Protect Podocytes in FSGS
Could a Simple Blood Test Help Identify Kidney Fibrosis in IgAN?
AudioAbstractsCould a Simple Blood Test Help Identify Kidney Fibrosis in IgAN?
Ryan Quigley
Key CKD Updates from the 2026 NKF Meetings
Clinician's RoundtableKey CKD Updates from the 2026 NKF Meetings
Charles Turck, PharmD, BCPS, BCCCP
Matthew R. Weir, MD
Suneel Udani, MD
What the Latest IgAN Clinical Trials Mean for Patient Care
On the Frontlines of IgA NephropathyWhat the Latest IgAN Clinical Trials Mean for Patient Care
Steve Jackson, PharmD
Andrew S. Bomback, MD, MPH
Gates B. Colbert, MD
Anjay Rastogi, MD, PhD
- advertisement
Targeting BAFF and APRIL in IgA Nephropathy
On the Frontlines of IgA NephropathyTargeting BAFF and APRIL in IgA Nephropathy
Gates B. Colbert, MD
Edgar V. Lerma, MD, FACP, FASN, FPSN (Hon)
Early Combination Therapy in IgA Nephropathy
On the Frontlines of IgA NephropathyEarly Combination Therapy in IgA Nephropathy
Gates B. Colbert, MD
Sayna Norouzi, MD
Reading the Warning Signs: Risk Stratification in IgAN
On the Frontlines of IgA NephropathyReading the Warning Signs: Risk Stratification in IgAN
Gates B. Colbert, MD
Dustin Le, MD, MHS
Not Just for Diabetes: Broadening uACR Screening to CV Risk Populations
Conversations in CV Risk AssessmentNot Just for Diabetes: Broadening uACR Screening to CV Risk Populations
Brian P. McDonough, MD, FAAFP
Anu Lala, MD
Unseen Disease: The Diagnostic Barriers to CKD and CV Risk Prevention
Conversations in CV Risk AssessmentUnseen Disease: The Diagnostic Barriers to CKD and CV Risk Prevention
Jennifer Caudle, DO, FACOFP
Dustin Le, MD, MHS
Niloo Nobakht, MD, FASN
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Heart MattersHypertension in Women: Cardiovascular Risk Across the Lifespan
Shelina Ramnarine, PhD
Payal Kohli, MD, FACC
- advertisement
Predicting the Heart’s Future: Albuminuria as a CV Warning Sign
Conversations in CV Risk AssessmentPredicting the Heart’s Future: Albuminuria as a CV Warning Sign
Brian P. McDonough, MD, FAAFP
Anu Lala, MD
Heart Failure and Albuminuria: Connecting the Dots
Conversations in CV Risk AssessmentHeart Failure and Albuminuria: Connecting the Dots
Jennifer Caudle, DO, FACOFP
Robert J. Mentz, MD, FHFSA, FACC
Bridging the Gap: From Screening to Cardiovascular Risk Diagnosis
Conversations in CV Risk AssessmentBridging the Gap: From Screening to Cardiovascular Risk Diagnosis
Jennifer Caudle, DO, FACOFP
Dustin Le, MD, MHS
Niloo Nobakht, MD, FASN